The Changing Landscape of Topical Therapies: A Fall Clinical Preview
Dermatology has always woven together science and artistry, the molecular with the tangible. As topical innovation surges ahead, balance is being redefined. At this year’s 25th Annual Fall Clinical Dermatology Conference in Las Vegas, that shift will come into sharp focus.
By Dermsquared Editorial Team
Dermatology has always woven together science and artistry, the molecular with the tangible. As topical innovation surges ahead, balance is being redefined. At this year’s 25th Annual Fall Clinical Dermatology Conference in Las Vegas, that shift will come into sharp focus during Dr. Peter Lio’s session, “The Changing Landscape of Topical Therapies,” a timely look at where we’ve been and what’s next.
For decades, topical corticosteroids anchored the therapeutic algorithm for inflammatory skin disease. They worked, but they were also limited. Concerns around long-term safety, tolerance, and patient satisfaction created gaps that many clinicians filled with off-label improvisation and systemic escalation. Today, those gaps are closing. With the approval of new non-steroidal options (from PDE4 inhibitors to aryl-hydrocarbon receptor (AhR) modulators) the field is entering a phase of refinement, not replacement.
Tapinarof: A Targeted Rethink of Inflammation
One of the most intriguing additions to the dermatology toolbox is tapinarof 1% cream, an AhR agonist that first earned FDA approval for plaque psoriasis in 2022 and, more recently, for adults and children as young as 2 years with atopic dermatitis in late 2024.
Dr. Lio’s lecture explores how tapinarof’s mechanism of action positions it apart from the conventional anti-inflammatory story. Rather than suppressing immune pathways broadly, tapinarof activates AhR, which in turn enhances skin-barrier function, normalizes oxidative stress responses, and downregulates pro-inflammatory cytokines. The result? Durable clearance, minimal local irritation, and patient satisfaction metrics that hold up beyond the 12-week mark.
Practical Implications for Daily Care
For clinicians, the appeal is as pragmatic as it is scientific. Topicals remain the first conversation in nearly every case of atopic dermatitis or psoriasis. Yet real-world adherence often falters at the intersection of irritation, complexity, and steroid-fatigue. Dr. Lio underscores how agents like tapinarof can re-energize that starting point. If a treatment can calm inflammation, repair the barrier, and be cosmetically elegant enough that patients actually apply it, then it’s more than just clearing skin, it’s changing behavior.
Beyond Molecules: A Mindset Shift
The longevity of Fall Clinical is rooted in translating data into decisions clinicians can use Monday morning. This year’s topical-therapy dialogue embodies that spirit. As Dr. Lio reminds clinicians in his presentation, the goal is not only to get clear, but to keep clear, and keep it up, through safer, more sustainable topical strategies. That’s not just pharmacologic progress—it’s cultural. It reflects a community of clinicians who expect topical innovation to be evidence-based and patient-centered; who value long-term disease control; and who see topical care as a partnership with patients not just a prescription.
See it unfold at Fall Clinical 2025
Expect fresh data, candid discussion, and the kind of practical clarity that defines this conference. Because the future of topicals isn’t just about what we apply, it’s about how we think.